Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

You may be eligible if

• Patients must have received either 2 or 3 prior chemotherapy regimens including adjuvant or neoadjuvant therapy.
• Prior treatment must have included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).
• Patients must have received a minimum cumulative dose of anthracycline or must be resistant to an anthracycline.
• Patients must be resistant to taxane therapy.
• Patients may not have any history of brain and/or leptomeningeal metastases.
• Patients may not have CTC Grade 2 or greater neuropathy (motor or sensory).
• Patients may have not have had prior treatment with an epothilone and/or capecitabine (i.e., Xeloda)